Citation, DOI, disclosures and article data
At the time the article was created Jan Frank Gerstenmaier had no recorded disclosures.View Jan Frank Gerstenmaier's current disclosures
Ioflupane (I-123) is a radiopharmaceutical for the diagnosis of Parkinson disease and its differential diagnoses, e.g. essential tremor versus tremor due to parkinsonian syndromes (idiopathic Parkinson disease, multiple system atrophy and progressive supranuclear palsy).
iodine-123 is a cyclotron product
decay by electron capture to tellurium-123
physical half-life is 13.22 hours
predominant energy of its gamma spectrum is 159 keV
Ioflupane is the international non-proprietary name of a phenyltropane compound, usually abbreviated to FCPIT (fluoropropyl beta-carbomethoxy-3 beta-(4-iodophenyltropane), a cocaine analog. Ioflupane has a high affinity for presynaptic dopamine transporters (DAT) which are abundant in the striatal region.
I-123 ioflupane is available worldwide and marketed under the trade name DaTSCANTM.
Uses, doses and timing
as a cyclotron product, the solution is supplied ready to inject
the dose reference activity of I-123 ioflupane is 185 MBq (5 mCi)
administration is intravenous
thyroid blocking with 120 mg potassium iodide 2 hours before and 24 hours after the injection is recommended
SPECT is typically performed 3-6 hours after injection
Reduced putaminal uptake as evidenced visually by the loss of the normal comma- or crescent-shaped uptake in the striatum and the appearance of abnormal period- or oval-shaped uptake in the caudate only is supportive of a diagnosis of a parkinsonian syndrome: